BACKGROUND: Albuminuria is a risk factor for chronic kidney disease progression, end-stage renal disease, cardiovascular events, and mortality. Animal studies suggested that vitamin D insufficiency may contribute to the pathogenesis of albuminuria. STUDY DESIGN: Cross-sectional study. SETTING & PARTICIPANTS: 15,068 adults participating in the Third National Health and Nutrition Examination Survey. PREDICTOR: Serum 25-hydroxyvitamin D concentration, examined in quartiles. OUTCOMES & MEASUREMENTS: Albuminuria, defined using established sex-specific cutoff values for urine albumin-creatinine ratio (25 to 2,999 mg/g for women, 17 to 2,999 mg/g for men). RESULTS: A stepwise increase in the prevalence of albuminuria was observed with decreasing quartiles of vitamin D concentration: 8.9%, 11.5%, 13.7%, and 15.8% (P < 0.001). Adjusting for age, sex, race/ethnicity, region and season of measurement, smoking status, body mass index, and estimated glomerular filtration rate, relative risks for albuminuria by decreasing quartile of vitamin D concentration were 1.00 (reference group), 1.14 (95% confidence interval, 0.95 to 1.37), 1.22 (95% confidence interval, 1.03 to 1.45), and 1.37 (95% confidence interval, 1.10 to 1.71; P = 0.006). Additionally adjusting for blood pressure and diabetes mellitus, these risks were somewhat attenuated and retained statistical significance. LIMITATIONS: The cross-sectional design of this study does not allow demonstration of temporal or causal relationships between vitamin D and albuminuria. CONCLUSIONS: Additional studies are needed to clarify the relationship of vitamin D with albuminuria and determine whether vitamin D therapy prevents or improves markers of kidney and cardiovascular disease.
BACKGROUND:Albuminuria is a risk factor for chronic kidney disease progression, end-stage renal disease, cardiovascular events, and mortality. Animal studies suggested that vitamin Dinsufficiency may contribute to the pathogenesis of albuminuria. STUDY DESIGN: Cross-sectional study. SETTING & PARTICIPANTS: 15,068 adults participating in the Third National Health and Nutrition Examination Survey. PREDICTOR: Serum 25-hydroxyvitamin D concentration, examined in quartiles. OUTCOMES & MEASUREMENTS: Albuminuria, defined using established sex-specific cutoff values for urine albumin-creatinine ratio (25 to 2,999 mg/g for women, 17 to 2,999 mg/g for men). RESULTS: A stepwise increase in the prevalence of albuminuria was observed with decreasing quartiles of vitamin D concentration: 8.9%, 11.5%, 13.7%, and 15.8% (P < 0.001). Adjusting for age, sex, race/ethnicity, region and season of measurement, smoking status, body mass index, and estimated glomerular filtration rate, relative risks for albuminuria by decreasing quartile of vitamin D concentration were 1.00 (reference group), 1.14 (95% confidence interval, 0.95 to 1.37), 1.22 (95% confidence interval, 1.03 to 1.45), and 1.37 (95% confidence interval, 1.10 to 1.71; P = 0.006). Additionally adjusting for blood pressure and diabetes mellitus, these risks were somewhat attenuated and retained statistical significance. LIMITATIONS: The cross-sectional design of this study does not allow demonstration of temporal or causal relationships between vitamin D and albuminuria. CONCLUSIONS: Additional studies are needed to clarify the relationship of vitamin D with albuminuria and determine whether vitamin D therapy prevents or improves markers of kidney and cardiovascular disease.
Authors: Bryan Kestenbaum; Ronit Katz; Ian de Boer; Andy Hoofnagle; Mark J Sarnak; Michael G Shlipak; Nancy S Jenny; David S Siscovick Journal: J Am Coll Cardiol Date: 2011-09-27 Impact factor: 24.094
Authors: Abigail B Shoben; Bryan Kestenbaum; Gregory Levin; Andrew N Hoofnagle; Bruce M Psaty; David S Siscovick; Ian H de Boer Journal: Am J Epidemiol Date: 2011-11-23 Impact factor: 4.897
Authors: Iris Sanchez; Roberto Mangoo-Karim; Jason R Stubbs; George P Yanev; James B Wetmore Journal: Int Urol Nephrol Date: 2012-05-30 Impact factor: 2.370
Authors: Ian H de Boer; Ronit Katz; Michel Chonchol; Joachim H Ix; Mark J Sarnak; Michael G Shlipak; David S Siscovick; Bryan Kestenbaum Journal: Clin J Am Soc Nephrol Date: 2011-08-11 Impact factor: 8.237